The FDA CRL expectation is the dominant catalyst — the stock will move on the binary outcome of the June 20 PDUFA date and the company's ability to resubmit in Q4 2026. The $180M financing removes near-term cash runway risk but the manufacturing issue introduces regulatory delay uncertainty. Monitor for any FDA communication before June 20 and the commercial leadership reorganization announcement expected today.
Price Chart
Executive Summary
Achieve Life Sciences reported Q1 2026 net loss of $10.2M ($0.19/share) vs $12.8M ($0.37/share) in Q1 2025, with operating expenses down to $10.5M from $12.9M. The company closed a $180M upfront private placement (up to $354M with milestone warrants), appointed a new CEO and board members, and disclosed it expects a Complete Response Letter from the FDA by June 20, 2026 due to a third-party manufacturer's facility receiving an Official Action Indicated classification, with plans to resubmit the NDA in Q4 2026 targeting a launch in H1 2027.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $10.2M ($0.19/share) vs $12.8M ($0.37/share) in Q1 2025 — narrower loss on lower operating expenses
- Closed private placement of up to $354M, including $180M upfront and up to $174M in milestone-based warrants
- Estimated net proceeds of ~$168.6M from the private placement after fees
- Expects to receive a Complete Response Letter from FDA on or before June 20, 2026 PDUFA date due to third-party manufacturer facility issues
- Intends to resubmit NDA in Q4 2026 naming Adare Pharma Solutions as new primary manufacturing partner
- Appointed Andrew D. Goldberg, MD as CEO and expanded board with three new directors
- Chief Commercial Officer Jaime Xinos departing effective May 31, 2026
- Cash, cash equivalents and marketable securities of $29.3M as of March 31, 2026 (excluding private placement proceeds)
Financial Impact
Q1 2026 net loss narrowed to $10.2M from $12.8M YoY; cash position of $29.3M will be supplemented by ~$168.6M net proceeds from private placement
Risk Factors
- FDA issues Complete Response Letter delaying approval timeline beyond H1 2027 launch target
- Third-party manufacturer remediation may not satisfy FDA requirements for resubmission
- Dilution from milestone-based warrants ($174M potential) if exercised
- Commercial leadership transition could disrupt launch preparations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218175 |
| Document: d854692d8k.htm | 0001193125-26-218175 |
| Document: 0001193125-26-218175-index-headers.html | 0001193125-26-218175 |
| Document: 0001193125-26-218175-index.html | 0001193125-26-218175 |
| Document: 0001193125-26-218175.txt | 0001193125-26-218175 |
| 8-K Data (Synthetic) | 0001193125-26-218175 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.57 (−9.32%) |
Oct 1, 2026 24d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.57 (−9.32%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.57 (+12.47%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.57 (−1.87%) |
Aug 11, 2026 10w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.57 (+3.03%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.57 (−1.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.57 (−18.93%) |
Jun 2, 2026 20w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.57 (+30.52%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.57 (−39.98%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.57 (+47.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers